Table 7.
Comparation of AE-incidences between combination groups and single agent groups of figitumumab
| AEs with a higher incidence in the combination group | A* (in total 61 patients) | % | B (in total 76 patients) | % | X2 | P |
|---|---|---|---|---|---|---|
| Decreased appetite | 14 | 0.23 | 2 | 0.03 | 13.5448 | 0.0002 |
| Diarrhoea | 22 | 0.36 | 6 | 0.08 | 16.5150 | 0.0000 |
| Thrombocytopenia | 17 | 0.28 | 4 | 0.05 | 13.3236 | 0.0003 |
| Neutropenia | 18 | 0.30 | 0 | 0.00 | 25.8184 | 0.0000 |
| Leukocytes | 18 | 0.30 | 0 | 0.00 | 25.8184 | 0.0000 |
| Neuropathy | 16 | 0.26 | 0 | 0.00 | 22.5704 | 0.0000 |
| AEs with a higher incidence in the single-agent group | ||||||
| Elevated AST/ALT | 0 | 0.00 | 9 | 0.12 | 5.9226 | 0.0149 |
| AEs with a similar incidence in the two groups | ||||||
| Hyperglycaemia | 3 | 0.05 | 8 | 0.11 | 0.7819 | 0.3766 |
| Nausea and vomiting | 5 | 0.08 | 6 | 0.08 | 0.0633 | 0.8013 |
| Fatigue | 13 | 0.21 | 9 | 0.12 | 2.2511 | 0.1335 |
| Skin reaction | 0 | 0.00 | 6 | 0.08 | 3.3276 | 0.0681 |
| Anaemia | 13 | 0.21 | 9 | 0.12 | 2.2511 | 0.1335 |
| Musculoskeletal pain | 4 | 0.07 | 2 | 0.03 | 0.4843 | 0.4865 |
| Pain | 0 | 0.00 | 2 | 0.03 | 0.3133 | 0.5757 |
| Headache | 0 | 0.00 | 3 | 0.04 | 0.9637 | 0.3262 |
| Weight decreased | 0 | 0.00 | 2 | 0.03 | 1.6290 | 0.2018 |
| Muscle spasm | 0 | 0.00 | 4 | 0.05 | 3.3071 | 0.0690 |
| Creatinine elevation | 0 | 0.00 | 2 | 0.03 | 0.3133 | 0.5757 |
*
A, number of AEs in combination group; B, number of AEs in single agent group.